Perseus Proteomics Inc., a portfolio company of Kyoto University Innovation Capital Corporation (Head Office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi; hereinafter "Kyoto iCAP"), was today listed on the Tokyo Stock Exchange Mothers market. The listing of Perseus Proteomics is the first listing for the "Innovation Kyoto 2016 Investment Limited Partnership" managed by Kyoto iCAP.

Perseus Proteomics is a drug discovery venture whose core business is the development of antibody drugs. The company has jointly applied for patents in collaboration with Kyoto University, and Professor Fuyuki Ishikawa of Kyoto University's Graduate School of Life Sciences serves as the company's scientific advisor.

Perseus Proteomics' development pipeline includes PPMX-T001, an anti-GPC3 antibody, and PPMX-T002, an anti-cadherin antibody, both of which have reached Phase 2. PPMX-T003, a unique antibody targeting transferrin, is in development for the treatment of refractory true polycythemia vera and is currently in Phase 1.

Outline of Perseus Proteomics Inc.

Establishment	February 2001
Business	Development of antibody drugs and novel diagnostic methods utilizing antibodies
Head Office Location	Meguro-ku, Tokyo
President & CEO	Takuya Yokogawa